Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.

J Laparoendosc Adv Surg Tech AJul 7, 2026 (epub)
Case ReportEndocrinologyGastroenterology

Valerio Cigaina, Alfredo Saggioro, Paolo Fabris et al.

✦ AI-curated · Sources linked

Case in brief

A 69-year-old male with a 25-year history of insulin-dependent type-2 diabetes underwent implantation of a Brain NeuroModulator (BNM) device in the gastric submucosa. Following the procedure, heart rate variability (HRV) analysis indicated increased parasympathetic tone. Within two months, the patient was able to discontinue semaglutide and metformin, and insulin was reduced to zero, demonstrating significant improvement in glycemic control.

Diagnostic / clinical pearl

This case highlights the potential of neuromodulation via gastric implantation to improve glycemic control in insulin-dependent type-2 diabetes by enhancing parasympathetic tone.

Source

PubMed · PMID 42414233

Published in J Laparoendosc Adv Surg Tech A. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.